Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tosedostat added to standard induction chemotherapy for AML or RAEB
NL-OMON22002Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tosedostat in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) (2 arms), sponsored by HOVON. Primary endpoints: Safety and tolerability in Part A, Complete remission rate in Part A and 2 more. Started Aug 2010; status: active, not recruiting.
02
Drugs
tosedostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on NL-OMON22002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22002.